| 八段锦应用于非小细胞肺癌的meta分析题录 |
| |
| 引用本文： | 胡安华 顾非. 八段锦应用于非小细胞肺癌的meta分析题录[J]. 国际医药卫生导报, 2023, 29(4): 465-470. DOI: 10.3760/cma.j.issn.1007-1245.2023.04.006 |
| |
| 作者姓名： | 胡安华 顾非 |
| |
| 作者单位： | 1上海市静安区静安寺街道社区卫生服务中心，上海 200040；2上海中医药大学附属岳阳中西医结合医院脊柱推拿科，上海 200437 |
| |
| 基金项目： | 上海市第二轮中医专家社区师带徒项目［ZY（2018-2020）-JCTS-1001］ |
| |
| 摘 要： | 目的系统评价八段锦应用于非小细胞肺癌的临床有效性。方法检索Pubmed、Embase(Ovid)、The Cochrane Library、Web of Science、中国知网(CNKI)、维普、万方、CBM数据库, 检索八段锦(或配合其他治疗方法)治疗非小细胞肺癌的随机对照试验(RCT), 检索时限设定为数据库各自建库时间至2022年7月26日。采用Stata 17软件进行meta分析, 根据Cochrane的系统评价员手册risk of bias标准评估偏倚风险进行文献质量评价。结局指标为肺功能测试[第一秒用力呼气量(FEV1)、用力肺活量(FVC)]、Borg呼吸困难评分、6 min步行试验、焦虑自评量表(SAS)、抑郁自评量表(SDS)、肺癌治疗功能评价量表(FACT-L)(4.0版)。结果共纳入6项RCT研究, 合计322例患者。meta分析显示, 试验组在FEV1测试结果[SMD=0.53, 95%CI(置信区间)(0.13, 0.94), P=0.01]、FVC测试结果[SMD=0.58, 95%CI(0.17, 0.98), P=0.005]、6 min步行试验结果[...
|
| 关 键 词： | 八段锦 非小细胞肺癌 meta分析 |
| 收稿时间： | 2022-10-12 |
Meta-analysis of Baduanjin for non-small cell lung cancer |
| |
| Hu Anhua,Gu Fei. Meta-analysis of Baduanjin for non-small cell lung cancer[J]. International Medicine & Health Guidance News, 2023, 29(4): 465-470. DOI: 10.3760/cma.j.issn.1007-1245.2023.04.006 |
| |
| Authors: | Hu Anhua Gu Fei |
| |
| Affiliation: | 1 Health Service Center of Jing'an-Temple Street Community, Jing'an District, Shanghai 200040, China; 2 Department of Spinal Massage,Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China |
| |
| Abstract: | Objective To systematically evaluate the clinical effectiveness of Baduanjin for patients with non-small cell lung cancer. Methods The databases, PubMed, EMBASE (Ovid), The Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Weipu, Wanfang, and CBM were searched for the randomized controlled trials (RCTs) on Baduanjin (or combined with other treatments) in the treatment of patients with non-small cell lung cancer from their establishment to July 26, 2022. Meta analysis was performed using the Stata 17 software. The risk of bias was assessed according to the Cochrane's Handbook for systematic reviewers' risk of bias criteria for literature quality assessment. The outcome measures were pulmonary function tests (FEV1 and FVC), Borg dyspnea score, 6-min walk test, Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and Functional Assessment of Lung Cancer Therapy (FACT-L) (version 4.0). Results Six RCTs with a total of 322 patients were included. Meta analysis showed that the test group had better FEV1 [SMD= 0.53, 95%CI (0.13, 0.94), P=0.01], FVC [SMD=0.58, 95%CI (0.17, 0.98), P=0.005], 6-min walk test [SMD=0.56, 95%CI (0.34, 0.79), P<0.01], and SAS score [SMD=-1.18, 95%CI (-1.51,-0.85), P<0.01] than the control group. The test group had significantly greater improvement in the Borg dyspnea score [SMD=-0.32, 95%CI (-0.72, 0.07), P=0.11], SDS [SMD=-0.62, 95%CI (-1.68, 0.44), P=0.253], and scores of physical status [SMD=0.35,95%CI(-0.44,1.13),P=0.385], social and family status [SMD=0.44, 95%CI (-0.29, 1.17), P=0.242], affective status [SMD=0.36, 95%CI (-0.31, 1.04), P=0.293], and additional concern [SMD=0.43, 95%CI (-0.41, 1.27), P=0.313] and total score [SMD=1.22, 95%CI (-0.18, 2.63), P=0.088] of FACT-L (version 4.0) than the control group, with statistical differences. Conclusions Baduanjin is able to improve the patients' lung function, exercise tolerance, and anxiety status; its effects on dyspnea, depression status as well as improvement on the functional assessment scale for lung cancer treatment are not significant, so it needs further study. |
| |
| Keywords: | Baduanjin Non-small cell lung cancer Meta analysis |
|
| 点击此处可从《国际医药卫生导报》浏览原始摘要信息 |
|
点击此处可从《国际医药卫生导报》下载免费的PDF全文 |
|
